Normalization of elevated liver enzymes due to V-1 Immunitor therapy

V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have exp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jirathitikal,Vichai, Metadilogkul,Orapun, Bourinbaiar,Aldar S.
Lenguaje:English
Publicado: Pontificia Universidad Católica de Valparaíso 2003
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582003000100010
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0717-34582003000100010
record_format dspace
spelling oai:scielo:S0717-345820030001000102003-08-18Normalization of elevated liver enzymes due to V-1 Immunitor therapyJirathitikal,VichaiMetadilogkul,OrapunBourinbaiar,Aldar S. V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1’s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.info:eu-repo/semantics/openAccessPontificia Universidad Católica de ValparaísoElectronic Journal of Biotechnology v.6 n.1 20032003-04-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582003000100010en
institution Scielo Chile
collection Scielo Chile
language English
description V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1’s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.
author Jirathitikal,Vichai
Metadilogkul,Orapun
Bourinbaiar,Aldar S.
spellingShingle Jirathitikal,Vichai
Metadilogkul,Orapun
Bourinbaiar,Aldar S.
Normalization of elevated liver enzymes due to V-1 Immunitor therapy
author_facet Jirathitikal,Vichai
Metadilogkul,Orapun
Bourinbaiar,Aldar S.
author_sort Jirathitikal,Vichai
title Normalization of elevated liver enzymes due to V-1 Immunitor therapy
title_short Normalization of elevated liver enzymes due to V-1 Immunitor therapy
title_full Normalization of elevated liver enzymes due to V-1 Immunitor therapy
title_fullStr Normalization of elevated liver enzymes due to V-1 Immunitor therapy
title_full_unstemmed Normalization of elevated liver enzymes due to V-1 Immunitor therapy
title_sort normalization of elevated liver enzymes due to v-1 immunitor therapy
publisher Pontificia Universidad Católica de Valparaíso
publishDate 2003
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582003000100010
work_keys_str_mv AT jirathitikalvichai normalizationofelevatedliverenzymesduetov1immunitortherapy
AT metadilogkulorapun normalizationofelevatedliverenzymesduetov1immunitortherapy
AT bourinbaiaraldars normalizationofelevatedliverenzymesduetov1immunitortherapy
_version_ 1718441711344025600